Biopharmaceutical News and Research

RSS

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Morria Biopharmaceuticals Plc, a biopharmaceutical company focused on novel, anti-inflammatory drugs, announced today that it will be presenting the results from its ICH compliant Phase II study of MRX-4>th EAACI Congress in London on June 7th. The results will be presented by the study's principal investigator Prof. Eric Bateman.

4 Jun 2010

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

Royal Philips Electronics and RXi Pharmaceuticals Corporation, a US-based biopharmaceutical company, today announced that they have entered into a joint research agreement to explore the benefits of combining proprietary technologies from both companies for the targeted delivery of experimental therapeutics based on RNA interference.

4 Jun 2010

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine fibroids (myoma) - a condition that affects millions of women worldwide.

4 Jun 2010

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

3 Jun 2010

Constellation Pharmaceuticals raises $22 million in Series B financing round

Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced that it has raised $22 million in a Series B financing round.

2 Jun 2010

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

Santarus, Inc., a specialty biopharmaceutical company, today announced that is has begun to enroll patients in the first study in its Phase III clinical program to evaluate the efficacy and safety of rifamycin SV MMX® for the treatment of patients with travelers' diarrhea.

2 Jun 2010

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity.

2 Jun 2010

Tetraphase Pharmaceuticals raises $45M in Series C financing

Tetraphase Pharmaceuticals, a clinical stage biopharmaceutical company utilizing breakthrough synthetic chemistry technology to discover and develop next-generation antibiotics, today announced that it has raised $45 million in a Series C financing.

2 Jun 2010

PAREXEL International establishes new brand identity "Right Where You Need Us"

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has established the new brand identity "Right Where You Need Us," which reflects various transformation initiatives focused on meeting the diverse requirements of the Company's clients.

From Parexel 1 Jun 2010

MediSapiens completes $1M seed round investment for personalized cancer medicine software

MediSapiens, world's first software company for personalized cancer medicine in oncology clinics and drug development, completed $ 1 million (EUR 0.8 million) seed round investment from Veraventure, ETFIII advised by Eqvitec Partners, VTT Ventures and Lifeline Ventures.

1 Jun 2010

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

Celladon Corp., a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, today announced that six-month data from its Phase 2 clinical trial of MYDICAR® show improvements in clinical outcomes and disease markers in advanced heart failure patients treated with the genetically targeted enzyme replacement therapy.

31 May 2010

HUYA Bioscience International forms strategic partnership with School of Chinese Materia Medica of BUCM

HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovation, today announced a strategic partnership with the School of Chinese Materia Medica of the Beijing University of Chinese Medicine (BUCM). As one of a series of collaborations that HUYA has established with China's leading research and development institutions, the agreement demonstrates HUYA's visionary commitment to enabling and accelerating the global development and commercialization of novel biopharmaceutical products originating in China.

29 May 2010

Shire receives Paragraph IV Notice Letter from Zydus over filing of ANDA for generic LIALDA

Shire plc, the global specialty biopharmaceutical company, announces that it has received a Paragraph IV Notice Letter today from Zydus Pharmaceuticals USA, Inc. advising of the filing of an Abbreviated New Drug Application ("ANDA") for a generic version of Shire's 1.2g mesalamine delayed release tablets, LIALDA(R).

29 May 2010

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced initiation of a Phase 2 proof-of-concept clinical trial to evaluate the preliminary efficacy and safety of its oncology drug candidate bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL).

29 May 2010

VaxGen signs definitive agreement to acquire diaDexus in stock-for-stock merger

VaxGen, Inc., a biopharmaceutical company, and diaDexus, Inc., a privately held diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, announced today that they have entered into a definitive agreement under which VaxGen will acquire diaDexus in a stock-for-stock merger.

29 May 2010

Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced the expansion of its collaboration with the U.S. Government to include the evaluation of Restanza's activity against sexually transmitted infections (STI's), such as gonorrhea.

28 May 2010

CrystalGenomics to merge with BexPharm

CrystalGenomics, Inc., a leading biopharmaceutical company developing novel small molecule therapeutics announced today that it will merge with BexPharm, a specialty pharmaceutical company that imports and distributes foreign market approved drugs in Korea.

28 May 2010

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

28 May 2010

NeoStem to present adult stem cell technologies at Stem Cell Investor & Executive Networking Conference

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced that the Company has been invited to present its adult stem cell technologies at the Stem Cell Investor & Executive Networking Conference Event (SCIENCE) in New York City on June 1, 2010. SCIENCE is designed to bring together investors with industry executives, visionary researchers and clinicians and other stakeholders to highlight opportunities and discuss advances in the stem cell field.

28 May 2010

IPS Research joins SAFE-BioPharma Association

IPS Research Company, a major southwest clinical research investigator site located in Oklahoma City, OK, has joined SAFE-BioPharma Association and taken another step in the process of eliminating paper copies from its operations.

28 May 2010

Biopharmaceutical News and Research

Morria Biopharmaceuticals to present Phase II study results of MRX-4 at EAACI Congress

Royal Philips Electronics, RXi Pharmaceuticals sign joint research agreement

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

Constellation Pharmaceuticals raises $22 million in Series B financing round

Santarus commences enrollment in rifamycin SV MMX Phase III clinical program for travelers' diarrhea

FDA accepts Orexigen's Contrave NDA for treatment of obesity

Tetraphase Pharmaceuticals raises $45M in Series C financing

PAREXEL International establishes new brand identity "Right Where You Need Us"

MediSapiens completes $1M seed round investment for personalized cancer medicine software

Celladon announces 6-month data from Phase 2 clinical trial of MYDICAR in advanced heart failure patients

HUYA Bioscience International forms strategic partnership with School of Chinese Materia Medica of BUCM

Shire receives Paragraph IV Notice Letter from Zydus over filing of ANDA for generic LIALDA

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

VaxGen signs definitive agreement to acquire diaDexus in stock-for-stock merger

Advanced Life Sciences expands partnership with U.S. Government to assess Restanza against STI's

CrystalGenomics to merge with BexPharm

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

NeoStem to present adult stem cell technologies at Stem Cell Investor & Executive Networking Conference

IPS Research joins SAFE-BioPharma Association

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News